Matches in UGent Biblio for { <https://biblio.ugent.be/publication/330095#aggregation> ?p ?o. }
Showing items 1 to 43 of
43
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B139294.
- aggregation creator B139295.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2006".
- aggregation format "application/pdf".
- aggregation hasFormat 330095.bibtex.
- aggregation hasFormat 330095.csv.
- aggregation hasFormat 330095.dc.
- aggregation hasFormat 330095.didl.
- aggregation hasFormat 330095.doc.
- aggregation hasFormat 330095.json.
- aggregation hasFormat 330095.mets.
- aggregation hasFormat 330095.mods.
- aggregation hasFormat 330095.rdf.
- aggregation hasFormat 330095.ris.
- aggregation hasFormat 330095.txt.
- aggregation hasFormat 330095.xls.
- aggregation hasFormat 330095.yaml.
- aggregation isPartOf urn:issn:1619-7070.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Re-188-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study".
- aggregation abstract "Purpose: The aim of this study was to investigate the feasibility of administering increasing activities of Re-188-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodol (Re-188-HDD/lipiodol) for the treatment of hepatocellular carcinoma (HCC) in patients with well-compensated cirrhosis. Methods: The activity levels were increased by 1.1 GBq/ step after a 6-week interval without unacceptable adverse events in at least five consecutive patients. Absorbed doses to the various organs were calculated according to the MIRD formalism, based on three gamma-scintigraphic studies. Response was assessed by means of MRI and alpha-fetoprotein (AFP) monitoring. Results: Thirty-five treatments were carried out in 28 patients. Activities from 4.8 to 7.0 GBq Re-188-HDD/lipiodol were administered via a transfemoral catheter. The mean absorbed dose to the liver ( including tumour) was 7.6 +/- 2.2, 9.8 +/- 4.9 and 15.2 +/- 4.9 Gy for the 4.8-, 5.9- and 7.0-GBq groups, respectively. Treatment was well tolerated at all activity levels. Further escalation of the administered activity was not feasible owing to limitations related to the radiolabelling procedure. Response assessment on MRI showed partial response, stable disease and disease progression in 1, 28 and 2 assessable treatments, respectively. In 8 of 17 treatment sessions with an initially elevated AFP, a reduction ranging from 19% to 97% was observed 6 weeks later. Conclusion: Following the intra-arterial administration of 4.8 - 7.0 GBq Re-188-HDD/lipiodol in patients with HCC and well-compensated liver cirrhosis, no severe adverse events occurred. Further escalation was not feasible owing to limitations in the radiolabelling procedure".
- aggregation authorList BK354979.
- aggregation endPage "352".
- aggregation issue "3".
- aggregation startPage "344".
- aggregation volume "33".
- aggregation aggregates 848499.
- aggregation isDescribedBy 330095.
- aggregation similarTo s00259-005-1954-1.
- aggregation similarTo LU-330095.